Clinical Trial Update: A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating donafenib plus S-1 for metastatic pancreatic cancer after nab-paclitaxel plus gemcitabine failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Donafenib (donafenib)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Fudan University | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: UNKNOWN